Indivior PLC
Case Overview
49 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 10/01/2024 |
Status: | Status: Investigating |
Company Name: | Company Name: Indivior PLC |
Court: | Court: Eastern District of Virginia |
Case Number: | Case Number: 3:24cv00554 |
Class Period: | Class Period: 02/22/2024 - 07/08/2024 |
Ticker: | Ticker: INDV |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Virginia on behalf of those who acquired Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) securities during the period of February 22, 2024 to July 8, 2024, inclusive (“the Class Period”). Investors have until October 1, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The lawsuit alleges that, throughout the Class Period, Indivior made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Indivior (i) grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products; (ii) overstated the financial prospects of SUBLOCADE, PERSERIS and OPVEE, and thus overstated the Company's anticipated revenue; (iii) knew that because of the negative impact of certain legislation on the financial prospects of Indivior's products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed FY 2024 net revenue guidance, including its FY 2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE; and (iv) knew that Indivior was at a significant risk of, and/or was likely to, cease all sales and marketing activities related to PERSERIS.
The lawsuit alleges that, throughout the Class Period, Indivior made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Indivior (i) grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products; (ii) overstated the financial prospects of SUBLOCADE, PERSERIS and OPVEE, and thus overstated the Company's anticipated revenue; (iii) knew that because of the negative impact of certain legislation on the financial prospects of Indivior's products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed FY 2024 net revenue guidance, including its FY 2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE; and (iv) knew that Indivior was at a significant risk of, and/or was likely to, cease all sales and marketing activities related to PERSERIS.